MDT - Insulet: Insulating Patients Investors Still Have To Wait

2024-03-28 09:44:31 ET

Summary

• Insulet Corporation, the maker of the Omnipod Insulin Management System, provides essential services to a patient group of 10 million diabetes patients and has experienced significant growth over the past decade.
• The company's wearable and discrete solution, Omnipod, has the potential for further adoption in the market, as injections are still the norm for diabetes treatment.
• Insulet sales and operating profits have been strong, but elevated expectations for future growth have caused the stock price to decline, presenting a potential buying opportunity.

At the start of the year, I called shares of Insulet Corporation (PODD) an interesting, yet expensive, story. The maker of the Omnipod Insulin Management System provides essential services to a targeted patient group of more than 10 million diabetes patients and has five-folded the business over the past decade....

For further details see: